Elizabeth Holmes Isn't the Real Con Job in Silicon Valley

Elizabeth Holmes Isn't the Real Con Job in Silicon Valley

Everyone loves a villain. Especially one with a black turtleneck and a baritone voice.

When whistleblowers step up to say Elizabeth Holmes is still spinning fantasies, rewriting history, or dodging accountability, the media machine lights up like a slot machine. Headlines scream about ongoing deception. Comment sections fill with righteous fury. We get our tidy moral drama: one woman fooled the world, got caught, went to prison, and now somehow still threatens the truth.

That story is comfortable. It is also lazy.

Obsessing over whether Elizabeth Holmes is "still lying" misses the far uglier reality of how modern biotech, venture capital, and diagnostic hype actually operate. Holmes was not a lone rogue genius who somehow hypnotized hardened institutional investors, seasoned board members, and sophisticated medical institutions into abandoning basic scientific rigor. She was a symptom. She was the loudest, most theatrical expression of an ecosystem that rewards storytelling over validation, speed over reproducibility, and valuation over clinical truth.

Calling out Holmes today feels like yelling at a broken alarm clock after the house has already been remodeled around the noise. The real danger isn't what one convicted founder says from behind bars or in interviews. The real danger is that Silicon Valley and big health tech learned all the wrong lessons from Theranos.


The Lazy Consensus About Theranos and "Ongoing Lies"

The standard narrative goes like this: Elizabeth Holmes built a fake blood-testing empire, deceived smart people, faced justice, and now any sign of continued spin or revisionism from her camp proves the con never truly ended.

Let's examine that premise. Of course people who build their entire identity around messianic founder mythology struggle to drop the script. Denial, rationalization, and selective memory are standard human defenses when everything collapses. Pointing out that someone whose life revolved around grandiosity is still spinning excuses is not an investigation. It is Tuesday.

The lazy consensus treats Theranos as an anomaly—a bizarre aberration in an otherwise disciplined system of due diligence, peer review, and clinical validation. Look closely at what actually happened, and that illusion shatters.

In diagnostic medicine, analytical accuracy is not a marketing claim. It is governed by concrete metrics: analytical sensitivity (the lowest concentration of a substance a test can reliably detect), analytical specificity (how well it avoids false positives from cross-reactive substances), precision (reproducibility across runs, instruments, and operators), and clinical validity (whether a measured value actually correlates with a patient's physiological state or disease outcome).

When you run dozens or hundreds of assays from a tiny finger-stick capillary sample, physics and fluidics push back hard. Capillary blood behaves differently from venous blood. Sample volumes are tiny. Microfluidics clog, evaporate, or suffer from cross-reactivity when multiple immunoassays or chemistries share tight spaces. Good engineers respect those constraints. Bad marketing pretends physics is a mindset issue.

I've seen companies blow millions on this exact delusion—convinced that proprietary software, sleek industrial design, or sheer founder willpower can bully biology into cooperating without years of grueling bench work and multi-site clinical trials. Spoiler: biology does not care about your pitch deck.


Why Asking "Is She Still Lying?" Is the Wrong Question

When readers type queries like Is Elizabeth Holmes still lying? or What is Elizabeth Holmes doing now? or Why did nobody stop Theranos sooner?, they are usually looking for closure. They want a clear line between the liar and the victims.

That line is blurrier than people admit.

"Why did nobody stop Theranos sooner?"

People ask this as if due diligence were a force field that magically activates whenever numbers look shaky. In reality, due diligence fails routinely when social proof and FOMO collide.

When heavyweight figures—former cabinet secretaries, generals, media titans, and prominent legal minds—sit on a board or lend credibility, many investors outsource their skepticism. Prestige acts as a substitute for technical literacy. Add proprietary "trade secret" secrecy—a classic shield in both defense and tech—and basic questions about validation data get brushed aside as "paranoia" or "not seeing the big picture."

Worse, diagnostic testing sits in an awkward gap for generalist tech investors. Software engineers know how to ship code fast and iterate in production. You cannot "move fast and break things" with blood chemistry without putting real patients at risk of misdiagnosis—delayed cancer treatment, unnecessary interventions, or missed infections. Treating biological assays like consumer apps is a category error dressed up as disruption.

"Did Elizabeth Holmes invent the playbook or just play it loudest?"

She played it loudest. She did not invent it.

Long before and long after Theranos, tech culture has celebrated fake-it-till-you-make-it as a virtue rather than a liability. Vaporware demos, cherry-picked pilot numbers, "stealth mode" mystique, and charismatic founders promising to transform trillion-dollar industries with one breakthrough are staples of modern venture capital.

John Carreyrou's investigative reporting in Bad Blood and subsequent courtroom testimony laid bare how heavily Theranos leaned on theatrical demonstrations and modified commercial analyzers rather than a working, validated proprietary box. Regulators like the Centers for Medicare & Medicaid Services (CMS) and investigators at the U.S. Securities and Exchange Commission (SEC) documented severe deficiencies in testing accuracy and truthfulness. Those facts are established on the public record.

Yet the culture that rewarded those traits barely flinched. Rebrand the buzzwords, swap out "blood testing" for "AI-powered diagnostics" or "predictive longevity," and the exact same hype cycle spins right back up.


Imagine a Scenario Where Founders Are Judged Like Bridge Engineers

Imagine a scenario where a startup founder pitches a new suspension bridge made from a "revolutionary lightweight composite." Instead of load testing, material fatigue studies, and independent structural engineering reviews, the founder shows a sleek 3D animation, puts a few famous names on the advisory board, and calls anyone asking for stress-test data "stuck in the past."

If that bridge opened to commuters without verified load limits, everyone would call it criminal negligence.

In healthcare and diagnostics, we sometimes let founders get disturbingly close to that line under the banner of "innovation." A false negative on an infectious disease or a false positive for a serious condition isn't a harmless UI bug you can patch over the weekend. It can change a person's medical care, mental health, and survival.

Real progress in medical diagnostics requires patience that venture timelines hate. It takes rigorous analytical validation, reference-method comparisons against gold-standard assays, proper quality control protocols, and transparent peer-reviewed or regulatory scrutiny. Less glamorous than a keynote speech. Far more likely to actually save lives.


The Uncomfortable Truth About My Own Contrarian Take

Taking a hard-nosed, ecosystem-level view carries a real risk: it can sound like letting individuals off the hook.

Let's be crystal clear. Institutional dysfunction does not erase individual responsibility. Choosing to mislead patients, regulators, or investors about test reliability is a choice. Whistleblowers like Tyler Shultz and Erika Cheung took massive personal, financial, and professional risks to speak up when speaking up was lonely and costly. Their courage mattered.

There is also another downside to zooming out too far. If you blame "the system" for everything, accountability gets diffused into fog. When nobody is personally responsible, nobody changes behavior. We need both: clear accountability for individuals who cross ethical and legal lines, and structural reforms in how capital, media, and institutions evaluate high-stakes claims.


What Smart Operators, Investors, and Patients Should Do Instead

If you work in biotech, invest in health tech, or simply read tech news trying to separate real breakthroughs from expensive theater, stop playing detective on old soap operas. Change how you evaluate claims.

  1. Demand primary evidence over founder charisma. Charisma is a performance skill, not a scientific instrument. Ask what was tested, on how many samples, against what gold-standard comparator, and what the error rates looked like in messy real-world conditions—not just controlled lab demos.
  2. Separate engineering demos from clinical validation. A prototype moving fluid or running a model on clean data is step one of a long march, not proof of clinical utility. Look for independent replication, clear definitions of sensitivity and specificity, and real-world workflow performance.
  3. Watch out for "secrecy" used to dodge basic questions. Intellectual property can be protected without hiding fundamental performance metrics from serious evaluators. When every basic technical question gets answered with non-disclosure rhetoric or vague vision statements, walk away.
  4. Ignore the loudest voice in the room. Hype correlates poorly with durability. The most transformative scientific and engineering advances usually sound quieter, more specific, and more constrained—because real experts know what can go wrong.

Stop waiting for one person to finally admit everything. Look at the incentives still sitting on the table.

The con isn't a single person talking to cameras. The con is pretending we learned our lesson while keeping the exact same incentives alive.

CB

Charlotte Brown

With a background in both technology and communication, Charlotte Brown excels at explaining complex digital trends to everyday readers.